Skin Appendage Disorders最新文献

{"title":"Retraction Statement: Paper by Ting Guo, Wenyu Li, and Sijian Wen Entitled \"Clinical Outcomes of Ritlecitinib in Treatment-Refractory Alopecia Areata: A Single-Center Real-World Study\" [Skin Appendage Disord, 2026; DOI: 10.1159/000553570].","authors":"","doi":"10.1159/sad/aesag009","DOIUrl":"https://doi.org/10.1159/sad/aesag009","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.1159/000553570.].</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13561528/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148944915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pigmented Onychomatricoma: Clinical and Dermoscopic Findings in a Series of 29 Cases.","authors":"Adriana Matter, Nilton Gioia Di Chiacchio, Jorge Ocampo-Garza, Glaysson Tassara Tavares, Nilton Di Chiacchio","doi":"10.1159/sad/aesag003","DOIUrl":"10.1159/sad/aesag003","url":null,"abstract":"<p><strong>Introduction: </strong>Pigmented onychomatricoma is a rare benign fibroepithelial tumor of the nail matrix that may clinically simulate subungual melanoma and other pigmented nail disorders. Because of its rarity and overlapping presentation with malignant nail unit tumors, recognition of its characteristic clinicodermoscopic findings is essential to avoid misdiagnosis and unnecessary aggressive surgical procedures.</p><p><strong>Methods: </strong>We retrospectively reviewed 29 patients with histopathologically confirmed pigmented onychomatricoma treated between 2015 and 2024. Demographic, clinical, and dermoscopic data were analyzed descriptively.</p><p><strong>Results: </strong>Seventeen patients were men (58.6%) and twelve were women (41.4%), with a mean age of 54 years (range 31-71 years). Fitzpatrick phototype IV predominated (58.6%). Longitudinal melanonychia was present in all patients (100%). The most frequent clinical findings were increased nail thickness (96.6%), increased transverse curvature (72.4%), and xanthonychia (51.7%). The most frequent dermoscopic findings were distal free-edge cavities (89.7%), splinter hemorrhages (62.1%), and parallel nail ridges (58.6%). Toenails were more frequently affected than fingernails (58.6% versus 41.4%), and the hallux was the most commonly involved digit (31%). The coexistence of longitudinal melanonychia, nail thickening, and characteristic distal cavities represented the most distinctive clinicodermoscopic pattern.</p><p><strong>Conclusions: </strong>Pigmented onychomatricoma demonstrates a consistent clinical and dermoscopic profile characterized by longitudinal melanonychia associated with nail thickening, characteristic distal cavities, and increased transverse curvature. Recognition of this constellation of findings is essential for differentiation from subungual melanoma and other pigmented nail tumors.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13594499/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149025963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"10.1159/000552016","DOIUrl":"10.1159/000552016","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1159/000549533.].</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":" ","pages":"323-324"},"PeriodicalIF":1.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13143327/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147842669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"10.1159/000552711","DOIUrl":"https://doi.org/10.1159/000552711","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1159/000551425.].</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13427357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148654351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Poor Therapeutic Response in Female Pattern Hair Loss: Mechanisms and a Practical Framework for Clinical Management.","authors":"Haoyu Li, Xin Zhang, Han Yang, Jiaxin Li, Jing Yang","doi":"10.1159/000553568","DOIUrl":"10.1159/000553568","url":null,"abstract":"<p><strong>Background: </strong>Female pattern hair loss (FPHL) is the most common cause of hair loss in women, yet therapeutic responses remain highly variable. A substantial proportion of patients experience persistent hair thinning or limited hair density improvement despite standard therapies, and current guidelines provide limited guidance for managing patients with poor therapeutic response.</p><p><strong>Summary: </strong>This review summarizes the major determinants of poor therapeutic response in FPHL, including pharmacogenetic factors, metabolic and endocrine comorbidities, treatment-related barriers, and advanced follicular miniaturization. Emerging evidence suggests that androgen receptor (AR) polymorphisms may influence antiandrogen responsiveness, whereas sulfotransferase (SULT1A1) activity may affect topical minoxidil efficacy. Obesity-related insulin resistance and polycystic ovary syndrome may further impair the follicular microenvironment through hyperandrogenism and chronic inflammation. Based on current evidence, we propose a practical three-step framework for evaluating poor responders: exclusion of pseudo-nonresponse, identification of metabolic-endocrine comorbidities, and incorporation of emerging biomarkers to support individualized treatment selection.</p><p><strong>Key messages: </strong>Poor therapeutic response in FPHL is multifactorial. Identifying the dominant contributing factor rather than simply escalating treatment intensity may facilitate precision management and improve outcomes in refractory patients.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13498328/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148798025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disconnect between Patient and Dermatologist Perceptions in Androgenetic Alopecia Therapy: Social Analysis across More than 100,000 Digital Conversations.","authors":"Archie Spindler, Derek Maas, Isabella Zappi, Reid Waldman, Natasha A Mesinkovska, Antonella Tosti, Jerry Shapiro, Kristen I Lo Sicco","doi":"10.1159/000553599","DOIUrl":"10.1159/000553599","url":null,"abstract":"<p><strong>Introduction: </strong>Individuals with alopecia encounter numerous treatment options and obtain guidance from both medical and nonmedical sources. Despite stronger clinical evidence for prescription therapies, many patients favor over-the-counter (OTC) products. We used large-scale social listening to characterize public sentiment toward androgenetic alopecia (AGA) treatments and compare perceptions of OTC and prescription modalities.</p><p><strong>Methods: </strong>Over 700,000 publicly available posts (March 2024-April 2025) from major online forums were captured using hair-loss-related keywords, filtered to approximately 143,000 human-authored conversations. These were analyzed for treatment associations, concerns, thematic content, and sentiment. OTC and prescription discussions were compared using chi-square testing (Bonferroni-corrected, two-sided α = 0.006).</p><p><strong>Results: </strong>Of included posts, 27,425 discussed prescription and 39,138 OTC therapies. Sentiment was dominated by frustration and anxiety, with low satisfaction. Prescription discussions more frequently referenced perceived lack of efficacy and side-effect concerns, whereas OTC discussions more often expressed positive themes, satisfaction, simplicity, and integration into personal routines. Prescription therapies were more commonly associated with skepticism, despair, and last-resort framing.</p><p><strong>Discussion: </strong>Public sentiment toward AGA treatments is largely negative and favors OTC therapies despite stronger evidence for prescription modalities. These perception gaps may contribute to delayed dermatologic care, underscoring the need for targeted education, expectation setting, and earlier engagement with evidence-based treatment.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13498327/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148798029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Yellow Nail Syndrome in Childhood: A Case Report Highlighting Diagnostic Challenges and the Possible Role of Nail Development-Related Genetic Variants.","authors":"Eylul Kasapoglu, Tugba Kevser Uzuncakmak, Ayse Mine Onenerk Men, Zehra Sahin","doi":"10.1159/000553550","DOIUrl":"https://doi.org/10.1159/000553550","url":null,"abstract":"<p><strong>Introduction: </strong>Yellow nail syndrome (YNS) is a rare disorder characterized by the triad of yellow nail discoloration, lymphedema, and respiratory manifestations. Pediatric cases are uncommon and often present incompletely, making diagnosis challenging. Although generally considered acquired, rare familial cases suggest possible genetic susceptibility.</p><p><strong>Case presentation: </strong>An 8-year-old girl presented with diffuse yellow nail dystrophy involving all 20 nails and recurrent unilateral swelling of the left lower extremity. Examination revealed yellow discoloration, dystrophy, and cuticle loss affecting all nails. Extensive multidisciplinary evaluation showed no systemic or respiratory involvement. Nail histopathology demonstrated dense bacterial aggregates resembling biofilm beneath the nail plate, while fungal studies were negative. Genetic analysis identified a heterozygous variant of uncertain significance in the <i>FZD6</i> gene, associated with nail morphogenesis, whereas <i>FOXC2</i> mutation analysis was negative. Conservative treatment with lymphedema exercises, compression bandaging, and topical therapy resulted in clinical improvement.</p><p><strong>Conclusion: </strong>This case highlights the diagnostic difficulty of pediatric YNS in the absence of the complete classical triad. YNS should remain in the differential diagnosis of children with unexplained nail dystrophy and recurrent extremity edema, even when systemic and genetic evaluations are inconclusive.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13480993/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148798009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nail Involvement in Refractory Pediatric Alopecia Areata: A Duration-Dependent Finding.","authors":"Ali Türkay, Tuğba Kevser Uzunçakmak, Server Serdaroğlu","doi":"10.1159/000553485","DOIUrl":"https://doi.org/10.1159/000553485","url":null,"abstract":"<p><strong>Introduction: </strong>Alopecia areata (AA) is an organ-specific autoimmune disorder producing non-scarring alopecia that ranges from isolated patches to total scalp loss (alopecia totalis, AT) or loss of all body hair (alopecia universalis, AU). Although the nail unit may also be affected and is widely regarded as a poor prognostic sign, data on its prevalence and correlates in children with refractory disease remain limited.</p><p><strong>Methods: </strong>We reviewed the records of 91 children (aged 3.5-14 years) with treatment-resistant AA, defined as disease duration ≥6 months, <10% improvement in Severity of Alopecia Tool (SALT) score after ≥2 adequate courses of conventional treatment, and ≥1 established poor prognostic factor. Nail morphology, SALT score-based severity, clinical subtype, sex, disease duration, and family history of AA were recorded. Chi-square and Fisher exact tests were applied (<i>p</i> < 0.05).</p><p><strong>Results: </strong>Sixty-three of 91 (69.2%) children had nail involvement. Pitting was the most common finding (47/63; 74.6%), followed by leukonychia (11.1%), trachyonychia (9.5%), longitudinal ridging (3.2%), and Beau's lines (1.6%). Nail involvement was significantly associated with longer disease duration (<i>p</i> = 0.049) but did not correlate with sex, clinical subtype, or scalp severity (all <i>p</i> > 0.05). Children without a family history of AA had significantly more severe disease and a higher proportion of AT or AU (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>Nail involvement was present in nearly 70% of children with treatment-resistant AA, far above rates reported in unselected cohorts. Association with disease duration but not scalp severity suggests that nail-matrix autoimmune activity may follow a partially independent course. Routine nail examination provides prognostic insights and may help guide treatment.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13493130/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148798007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plant-Derived Extracellular Vesicles Delivered by Microinfusion Microneedling for Androgenetic Alopecia: A Retrospective Case Series.","authors":"Francisco José Rodríguez-Cuadrado, Adrián Imbernón-Moya, Patricia Burgos-Blasco, Masiel García-Fernández, Marina Barletta","doi":"10.1159/000553389","DOIUrl":"https://doi.org/10.1159/000553389","url":null,"abstract":"<p><strong>Introduction: </strong>Extracellular vesicles (EVs), often referred to in the literature as \"exosomes,\" have emerged as candidate biologic mediators for hair restoration, but clinical evidence remains limited. Microinfusion of drugs into the skin (MMP®) is a tattoo device-based technique that combines microneedling with controlled intradermal delivery and may offer a reproducible way to administer scalp treatments.</p><p><strong>Methods: </strong>We performed a retrospective case series of adults with androgenetic alopecia (AGA) treated with a plant-derived EV formulation delivered through MMP®. Patients underwent 6 monthly sessions. Treatment tolerance, patient-reported outcomes, and blinded investigator assessments from standardized clinical photographs and site-matched trichoscopy were reviewed.</p><p><strong>Results: </strong>Twenty patients were included. Tolerance was favorable: 85% reported no adverse effects and 15% reported mild procedural pain. Subjectively, 95% of patients perceived improvement after six sessions, including 55% who reported marked improvement. Blinded evaluation also suggested benefit, more clearly at the clinical level than at the trichoscopic level. Mean clinical ratings indicated mild-to-marked improvement in 70% of cases, whereas mean trichoscopic ratings indicated mild-to-marked improvement in 50% and stabilization-to-mild improvement in 45%.</p><p><strong>Conclusion: </strong>In this retrospective series, plant-derived EVs delivered by MMP® were feasible, well tolerated, and associated with favorable subjective and blinded efficacy signals in patients with AGA.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13476083/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148762104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-Analysis of Incidence, Risk, Subtypes, and Mechanisms.","authors":"Gerardo Uriel Viquez Burboa, Miguel Ángel Rafael Flores Guillén, Vania Sofia Duardo González","doi":"10.1159/000553070","DOIUrl":"https://doi.org/10.1159/000553070","url":null,"abstract":"<p><strong>Introduction: </strong>GLP-1 receptor agonists (GLP-1 RAs) are among the fastest-growing pharmacological classes globally. Alopecia has emerged as a clinically relevant adverse effect signal, yet pooled quantitative estimates of risk by subtype and agent are lacking. The objective of this study was to estimate the pooled risk of alopecia associated with GLP-1 RA use, stratified by subtype, agent, and follow-up duration, and to synthesize mechanistic and management evidence.</p><p><strong>Methods: </strong>PubMed/MEDLINE, Embase, Cochrane Central, Web of Science, and Scopus were searched from inception to March 31, 2026, with no language restrictions. Studies reporting alopecia outcomes in adult GLP-1 RA users were eligible, including cohort studies, pharmacovigilance disproportionality analyses, and case series (<i>n</i> ≥ 5). Of 1,847 identified records, 17 met eligibility criteria. Random-effects meta-analyses (DerSimonian-Laird) were performed for odds ratios (ORs) and reporting ORs (RORs). The protocol was prospectively registered in PROSPERO (CRD420261335458) and PRISMA 2020 guidelines were followed.</p><p><strong>Results: </strong>Seventeen studies encompassing 1,091,743 patient-exposures were included. The pooled OR for any non-scarring alopecia was 1.40 (95% CI: 1.33-1.48; <i>I</i> ² = 0%; 3 cohort studies). Significant associations were found for telogen effluvium (aOR, 1.76; 95% CI: 1.34-2.32) and androgenetic alopecia (aOR, 1.64; 95% CI: 1.35-1.99) at 12 months; alopecia areata was not significant (aOR, 1.08; 95% CI: 0.87-1.34). Pharmacovigilance signals were highest for semaglutide (ROR, 2.46; 95% CI: 2.14-2.83) and tirzepatide (ROR, 1.73; 95% CI: 1.43-2.10). Paradoxically, 58% of patients with central centrifugal cicatricial alopecia showed improvement with GLP-1 RA use.</p><p><strong>Conclusion: </strong>GLP-1 RAs are associated with a significant 40% increased risk of non-scarring alopecia, driven by telogen effluvium and androgenetic alopecia and primarily mediated by weight loss-induced micronutrient deficiency. Semaglutide and tirzepatide carry the highest pharmacovigilance burden. Dermatologists should counsel patients proactively, optimize nutrition, and avoid premature drug discontinuation.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13489628/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148797972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}